“Chris Klomp, CMS’s director of Medicare and lead negotiator for the MFN drug pricing deals, said at an Aspen Institute event in June that he’s expecting the pilot program to be cost-neutral over a 24…”
“He also said he expects the number of Medicare beneficiaries who will participate in the pilot program to be within the single-digit millions initially.”
